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Abstract
Soluble guanylyl cyclase (sGC) is one of the key enzymes of 
the  nitric-oxide  (NO)/cyclic  3',5'-guanosine  monophosphate 
(cGMP) pathway. Located in virtually all mammalian cells, it 
controls the vessel tone, smooth muscle cell growth, platelet 
aggregation, and leukocyte adhesion. In vivo sGC activity is 
mainly regulated by NO which in turn is released from L-ar-
ginine by nitric oxide synthases. One of the main diseases of 
the cardiovascular system, endothelial dysfunction, leads to a 
diminished NO synthesis and thus increases vessel tone as 
well as the risk of thrombosis. The predominant therapeutic 
approach to this condition is a NO replacement therapy, as 
exemplified by organic nitrates, molsidomin, and other NO re-
leasing  substances.  Recent  advances  in  drug  discovery 
provided a variety of other approaches to activate sGC, which 
may help to circumvent both the tolerance problem and some 
non-specific  actions  associated  with  NO donor  drugs.  Sub-
stances like BAY 41-2272 stimulate sGC in a heme-dependent 
fashion and synergize with NO, allowing to enhance the effects 
both of endogenous NO and of exogenous NO donors. On the 
other  hand,  heme-independent  activators like  BAY 58-2667 
allow to activate sGC even if it is rendered unresponsive to NO 
due to oxidative stress or heme loss. Furthermore, a few sub-
stances have been described as specific inhibitors of sGC that 
allow to alleviate the effects of excess NO production as seen 
in septic shock. This review discusses the cardiovascular ef-
fects of heme-dependent and heme-independent activators as 
well as of inhibitors of sGC.
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INTRODUCTION
The nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) sig-
nal transduction pathway is a common mechanism which controls 
the blood vessel tone [1], the growth rate of vascular smooth muscle 
cells [2], the aggregation of thrombocytes [3], and the adhesion of 
leucocytes to the vessel wall [4]. NO activates soluble guanylyl cyc-
lase (sGC) which leads to an increased synthesis of cGMP. Carbon 
monoxide (CO) is another gaseous signalling molecule which at least 
partially acts through the same heme protein. CO seems to play an 
important role in the prevention of atherosclerotic lesions [5], pro-
tects against ischemia/reperfusion injury in the heart [6,7], attenu-
ates neointima formation after balloon angioplasty [5,8], inhibits ap-
optosis of vascular cells [9,10], regulates the blood vessel tone in 
some vascular beds [11], and has an antiaggregatory effect on plate-
lets [12]. As with all regulatory mechanisms in higher organisms, 
there is a well-tuned balance between the cGMP-mediated transduc-
tion systems and other signal transduction pathways that affect the 
cardiovascular system. However, pathological conditions may cause 
a reduced bioavailability of NO, an excess production of NO, or a re-
duced effect of NO. Along the same lines, a reduced or increased 
production of  CO accompanies a  variety  of  diseases.  This  review 
summarizes the biochemical background as well as the recent ad-
vances in the development of sGC-targeted therapies of cardiovascu-
lar diseases.
SIGNAL TRANSDUCTION BY SOLUBLE GUANYLYL 
CYCLASE AND CYCLIC GUANOSINE 
MONOPHOSPHATE
The NO/cGMP system had been the target of cardiovascular drugs 
long before the underlying mechanisms began to emerge. As early as 
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1867  amyl  nitrite  was  administered  to  relieve  the  symptoms  of 
angina pectoris [13]. Glyceryl trinitrate (GTN), a substance which is 
still a mainstay of antianginal therapy today [14,15], was found to 
be even more effective only a few years later [16]. However, it took 
almost a century until the increased synthesis of cGMP by soluble 
guanylyl cyclase (sGC) upon exposure to nitric oxide and GTN was 
established [17,18] and until the action of GTN was attributed to the 
release of NO [19].  This was seen as an exciting pharmacological 
principle back then, but the seminal work of  Furchgott et al.   [20]  
who first described the release from the endothelium of a relaxing 
factor (EDRF) after acetylcholine administration, and the identifica-
tion of this factor as NO or a closely related species [21-23] showed 
that a variety of cells are capable of generating NO themselves. Only 
four years later the first isoenzyme of a family of enzymes respons-
ible for generating NO (nitric oxide synthase, NOS) was purified [24].
Nitric oxide is synthesized by NOS, of which three isoenzymes are 
known (Table 1). A fourth isoenzyme, called mtNOS, has been isol-
ated from mitochondria. This isoform seems to be involved in medi-
ating oxidative injury in ischemia/reperfusion [25], but its role in 
the healthy vascular system, if any, is currently unclear [26]. The 
structurally related extramitochondrial enzymes differ in their tissue 
distribution as well as in their mechanisms of regulation [27,28]. Of 
these, the isoforms NOS-2 and NOS-3 are involved in a variety of 
vasculopathies.  NOS-3  is  constitutively  expressed  in  endothelial 
cells  and in  a  variety  of  blood  cells  like  platelets.  Its  activity  is 
strongly dependent on intracellular  Ca
2+
 which may change on a 
small timescale. Both its level of expression and its activity are regu-
lated by mechanical as well as by humoral factors [29,30]. The main 
purpose of  this isoenzyme is to link hemodynamic stimuli  (shear 
stress,  distension)  and  hormonal  signals  to  the  synthesis  of  NO 
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which in turn acts on the smooth muscle layer, causing a relaxa-
tion, as well as on blood cells, inhibiting aggregation and/or adhe-
sion [31]. On the other hand, NOS-2 is mainly a mediator of unspe-
cific host defense [32], which is upregulated in macrophages, mono-
cytes, and other cells in response to stimuli like interferon γ (IFN-γ), 
tumor necrosis factor α (TNF-α), interleukin 1, and lipopolysacchar-
ide (LPS) [33,34]. Once expressed at an elevated level, NOS-2 pro-
duces large quantities of NO for sustained periods of time. There-
fore, even though NOS-2 may contribute to the basal level of NO 
production in healthy vessels, it plays a major role in the cardiovas-
cular  system  mainly  by  causing  the  hypotensive  and  vasoplegic 
state characteristic for circulatory shock.
The main cellular target of NO is sGC. The structure and function of 
this enzyme will be dealt with in more detail in the following section. 
The association of NO with the heme moiety of sGC increases the 
rate of synthesis of cGMP from guanosine triphosphate (GTP) up to 
200-fold,  leading  to  an  increase  in  the  intracellular  steady-state 
concentration of this second messenger up to approx. 30-fold [17]. 
cGMP in turn binds to two different binding motifs in a variety of ef-
fector proteins. The first one is shared by protein kinase G (PKG), 
cAMP-dependent protein kinase (PKA), and cyclic nucleotide-gated 
cation channels. The other one is found in cGMP-regulated phos-
phodiesterases (PDE) [35]. cGMP binding affects the activity of the 
target enzymes and thus causes the cellular effects of an elevated 
cGMP level. Effects of NO and of NO-releasing compounds which are 
not mediated by cGMP have been reviewed elsewhere [36].
Like any other well-designed signalling system, the cGMP levels are 
controlled both by the rate of synthesis and by the rate of degrada-
tion.  The latter  is influenced mainly by various isoforms of  PDE, 
which hydrolyze  the  second messenger  to  the  inactive  guanosine 
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monophosphate (GMP) [37,38], and by extrusion into the extracellu-
lar space [39].
We now know that NO is not the only gaseous transmitter in the 
cardiovascular system. CO is another diatomic gas with strikingly 
similar properties compared to NO, with the exception that it is not 
a radical (we will not cover hydrogen sulfide as the third "gasotrans-
mitter" [40] here as its cardiovascular actions do not involve an in-
teraction with sGC [41-43]). CO is generated from heme, the ubi-
quitous cofactor of hemoproteins like the cytochromes and the oxy-
gen carrier hemoglobin. The synthesis of heme is a sequence of co-
ordinated reactions that occur partly in the cytosol, whereas the fi-
nal assembly of the ring structure and the insertion of the central 
iron occurs in mitochondria [44]. The enzymes responsible for the 
oxidative release of CO from heme are isoenzymes of the heme oxy-
genase (HO) family of enzymes and are located in microsomes. This 
rate-limiting  step  in  the  degradation  of  heme  yields  equimolar 
amounts of biliverdin IXa, CO, and ferrous iron. Biliverdin IXa is 
further transformed by biliverdin reductase to the potent antioxid-
ant bilirubin, whereas the free iron has to be sequestered immedi-
ately by ferritin to avoid the catalysis of reactions leading to reactive 
oxygen species [45-47]. CO is derived from the α-methene carbon of 
heme. Its removal causes the ring structure to open. CO has initially 
been viewed as  a  byproduct  of  a  purely  catabolic  mechanism to 
break down heme [48]. However, the discovery of the isoforms HO-2 
[49] and HO-3 [50] in addition to the one originally identified in rat 
liver and spleen (now called HO-1) sparked further interest in pos-
sible non-catabolic roles of the heme degradation (see also Table 1). 
HO-1  is  an  inducible  enzyme,  whereas  HO-2  is  expressed  con-
stitutively. The existence of HO-3 as a separate gene has later been 
drawn into question as the transcripts are likely to be alternatively 
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processed transcripts of the HO-2 gene [51].  HO-1 and HO-2 are 
both expressed in the brain (among other tissues) with a very dis-
tinct  distribution between brain regions and individual  cell  types 
[52]. Especially the hippocampus expresses high levels of HO isoen-
zymes as well as sGC, but contains only a small population of neur-
ons expressing NOS [53]. This finding strongly suggested a role of 
CO as a signalling molecule in at least some regions of the brain, a 
conclusion that was later extended to other tissues as well.
The  cardiovascular  system  is  capable  of  generating  substantial 
amounts CO, due to the abundance of the substrate heme and to a 
high level of HO activity [54,55]. Heme oxygenase activity is found 
both in smooth muscle cells [56,57] and in endothelial cells [58]. 
There are several targets for the signalling molecule CO in the vas-
culature. One of them is sGC, in a striking resemblance to NO, with 
further details given in the next section. Other known targets are 
large-conductance potassium channels [59-61], which act as oxygen 
sensors [62], and cytochrome P450 enzymes [63].
isoform alternative names regulation tissue distribution
NOS-1 nNOS (neuronal) Ca2+, HSP90, phos-
phorylation
central and peripheral 
neurons, nonadrenergic 
and noncholinergic neu-
rons, islets, endome-
trium, skeletal muscle
NOS-2 iNOS (inducible) (Ca2+), LPS, cyto-
kines, glucocorticoids
macrophages, liver, 
smooth muscle, endo-
thelium, heart
NOS-3 eNOS (endothelial) Ca2+, HSP90, myris-
toylation, palmitoyla-
tion,  phosphorylation
endothelium, brain, 
heart
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HO-1 HSP32 heat, hypoxia, oxidat-
ive stress
heart, liver, spleen, kid-
ney, brain
HO-2 hypoxia, redox sta-
tus, adrenal glucocor-
ticoids
brain, liver, endotheli-
um, testis
HO-3 HO-3a/HO-3b
Table 1: Isoforms of nitric oxide synthase (NOS) and of heme oxy-
genase (HO). The alternative NOS names refer to the tissue from 
which the isoform was first isolated (nNOS, eNOS) or to the most ob-
vious difference to the other isoforms (iNOS) and are given solely for 
reference  to  older  literature  (compiled  from  [27],  [28],  [51],  [52], 
[234]).
STRUCTURE AND FUNCTION OF SOLUBLE 
GUANYLYL CYCLASE
In order to understand the pharmaceutical approaches targeted at 
sGC, a thorough understanding of the structure and function of this 
enzyme is helpful. This section attempts to summarize our current 
knowledge about the structure of sGC as well as of the mechanisms 
available to activate and to inhibit this enzyme. As the focus is on 
the molecular mechanisms, we'll cover only "archetypical" agents in 
this section. A full coverage of the substances in use for therapeutic-
al or experimental purposes will be provided in a subsequent sec-
tion.
sGC (GTP pyrophospate-lyase, EC 4.6.1.2) is a member of the family 
of  nucleotide  cyclizing  enzymes,  along  with  adenylyl  cyclase  and 
particulate  guanylyl  cyclases [64].  All  of  these  enzymes  share  a 
strong homology of the catalytic domains, as each of these enzymes 
catalyzes the same cyclic 3'-5' phosphorylation of either adenosine 
triphosphate  (ATP)  or  guanosine  triphosphate  (GTP).  Mammalian 
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adenylate cyclases and particulate guanylyl cyclases are transmem-
brane proteins which are activated by the G protein α subunit and 
by natriuretic peptides, respectively. sGC, on the other hand, is a 
soluble dimeric enzyme which consists of an α subunit and a some-
what smaller β subunit [65]. There are two variants of each subunit 
known in humans [66], although only the α
1
/β
1
 (the predominant 
form) and the α
2
/β
1
 (mainly found in the brain) heterodimers were 
confirmed in vivo [67]. The α
1
/β
1
 isoform was shown to be respons-
ible  for  most  but  not  all  of  the  sGC-mediated  vasorelaxation  in 
knockout mice [68]. Each heterodimer contains a single heme moi-
ety [69,70] whose ferrous iron is coordinated by four nitrogens of the 
porphyrinic  ring  and  another  nitrogen  provided  by  the  histidine 
residue His-105 of the β-subunit as an axial ligand [71]. The heme 
is essential for the activation of the enzyme by nitric oxide [72,73] 
and by the closely related nitroxyl anion NO
-
 [74]. In the basal state, 
this heme iron is in a pentacoordinate high-spin state [75]. Binding 
of NO on the distal side results in an intermediate hexacoordinate 
complex, which is transformed in a rate-limiting step into a pentaco-
ordinate complex by breaking the iron-histidine bond [76,77].  An 
analysis of a bacterial cytochrome c' with a heme binding domain 
strikingly similar to that of sGC suggests that the rate-limiting step 
actually may involve a second NO molecule, which replaces the his-
tidine as the axial ligand on the proximal side, causing the initially 
bound NO on the distal side to leave [78]. The formation of the fer-
rous nitrosyl-heme complex increases the activity of  sGC approx. 
200-fold in the presence of Mg
2+
-GTP as substrate. The sensitivity of 
the enzyme towards NO activation is further modulated by a Ca
2+ 
dependent mechanism which causes sGC to associate with the cell 
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membrane, especially in caveolae close to NOS [79-81].
CO is also known to activate sGC [12,82] as it can bind to the heme 
moiety of sGC in a similar fashion as NO [70,83,75]. There has been 
some debate as to whether CO binding to the heme moiety alone is 
sufficient to activate the enzyme. Early reports failed to find a signi-
ficant activation by CO [83,84], while it is now commonly accepted 
that there is an up to 15-fold activation of cGMP synthesis upon CO 
binding when the experiments are performed in the absence of en-
vironmental NO [69]. Spectral studies revealed that CO also binds to 
the heme on the distal side, but does not cause the iron-histidine 
bond to break [85]. This leaves the iron-CO complex in a hexaco-
ordinate  state,  which partially  explains the different  activation of 
sGC by NO and CO. A thorough structural analysis of the heme-
binding  domain  of  sGC  revealed  that  both  NO  and  CO  binding 
causes the heme to pivot, but to a different degree [77].
The dissociation of the heme ligand offered additional insight in the 
activation mechanism. An analysis of the dissociation of NO allowed 
to distinguish two pentacoordinate heme-nitrosyl complexes which 
are in a slow equilibrium. Only one of these states ("open") has a 
high  activity,  whereas  the  other  one  ("closed")  results  in  a  slow 
cGMP synthesis. The "open" state rapidly equilibrates with a hexa-
coordinate form that can eventually release the NO to return to the 
pentacoordinate heme-histidin complex which displays basal activ-
ity [86,87].
Several sGC inhibitors have been described so far, among them su-
peroxide [82],  methylene  blue  and  6-anilino,5,8-quinolinedione 
(LY83583) [88],  1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one  (ODQ) 
[89,90],  and  4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-
1-one (NS 2028) [91]. The common mechanism of these inhibitors 
appears to be the oxidation of the ferrous heme iron to ferric iron 
10
Cardiovascular Effects of sGC modulation
either directly or via the generation of reactive oxygen species, leav-
ing the iron incapable of binding NO or CO. Enzyme activation by 
NO can usually be restored by reducing the heme iron with dithion-
ite [92]. So, strictly speaking, these substances are not classic en-
zyme inhibitors but they rather prevent the activation of the enzyme 
by heme ligands, which still allows for a basal cGMP synthesis to 
occur. The inhibiting effect of N-methylhydroxylamine is competitive 
to NO donors like sodium nitroprusside (SNP) which suggest either 
an interaction with heme or a NO scavenging effect [93].
In 1994 a new class of sGC modulators was discovered with the de-
scription of the antithrombotic properties of 3-(5'-hydroxymethyl-2'-
furyl)-1-benzyl indazole (YC-1) in rabbits and mice [94]. It was later 
established that YC-1 can stimulate sGC in the absence of NO [95] 
and to a small degree even in the absence of heme [96], but its ac-
tion is greatly enhanced if the reduced heme is present [97]. How-
ever, spectroscopic studies indicate that YC-1 is unlikely to bind to 
the heme moiety [69,98]. Moreover, the activation by YC-1 is syner-
gistic with NO, allowing an enzyme activation up to 800fold, and can 
be blocked by ODQ [69]. Even more intriguing, YC-1 allows CO to 
activate sGC to a degree similar to NO [69,99]. There are conflicting 
data about the exact binding site and the mechanism of action of 
YC-1. Photoaffinity labelling with BAY 51-9491, a substance struc-
turally related to YC-1, suggested an interaction of YC-1 with the 
cysteine residues 238 and 243 of the regulatory domain of the α
1 
subunit [100]. However, a homodimer consisting of two truncated β
1 
subunits still interacted with YC-1, suggesting a binding site in the 
N-terminal region of the β subunit which comprises the correspond-
ing regulatory domain of  that  subunit [101].  On the other hand, 
point mutations in the catalytic domains of the subunits resulted in 
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an enzyme unresponsive to YC-1 [102]. It is probably impossible to 
reconcile these data without further knowledge of the 3D structure 
which is still unknown. One working hypothesis is the insertion of 
YC-1 into the hydrophobic interface between the regulatory domains 
of both subunits.  This seems feasible as the furane and indazole 
rings  of  YC-1  are  coplanar,  whereas  only  the  ring  of  the  benzyl 
residue lies perpendicular to the former [103]. As both the binding 
of YC-1 and the alteration of the heme pocket elicited by NO or CO 
binding have to be transmitted by structural changes to the catalyt-
ic domains, a reverse effect of mutations in these areas on the bind-
ing of YC-1 is not unlikely. The discovery of further stimulators of 
sGC, which will be described in detail shortly, was greatly simplified 
by sGC overexpressing cell lines suitable as readout systems in high 
throughput screening assays [104], and their characterization was 
facilitated by novel methods to express and purify milligram quantit-
ies of recombinant sGC [69,105].
Several investigations attempted to find a molecular explanation for 
the synergistic effect of YC-1 and heme ligands. Two mechanisms 
are likely to contribute to the observed effect. First, YC-1 appears to 
weaken the His-iron bond in the hexacoordinate NO and CO bound 
states, which would reasonably explain the high sGC stimulation by 
CO in the presence of YC-1 [106]. Second, it is now generally accep-
ted  that  YC-1  decelerates  the  dissociation  of  the  heme  ligand 
[107,108,85,109,102] and thus increases the likelyhood that the en-
zyme is in the pentacoordinate "open" state [86]. In other words, YC-
1 is a moderately effective stimulator of sGC in the absence of a 
heme ligand, but a strong deactivation inhibitor of NO or CO activ-
ated sGC.
Before NO was identified as an endogenous sGC modulator, heme 
analogs were discussed as a regulatory mechanism [76]. Protopor-
12
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phyrin IX (a heme lacking the central iron) and hematoporphyrin IX 
(a protoporphyrin IX with slightly modified side chains) were shown 
to  activate  heme-free  sGC,  whereas  ferriprotoporphyrin  IX  (heme 
with a ferric iron) acted as a potent inhibitor [84,110]. BAY 58-2667 
was the first activator not based on a porphyrin structure which ap-
pears to act by binding to the heme binding domain of sGC [111], 
thus displacing the heme and freeing the His-105. A space-filling 
electronic model of BAY 58-2667 exhibited a striking similarity with 
heme in terms of the 3D-structure, the charge distribution, and the 
position  of  residues  critical  for  attaching  to  the  binding  domain 
[112].  The  substance  was  shown  to  interact  with  the  invariant 
amino acids Tyr-135 and Arg-139 of the β subunit. In contrast to 
NO, CO, or YC-1, BAY 58-2667 has the unique ability to activate 
sGC if the heme is oxidized or if it is removed entirely from the en-
zyme.
Taken together, therapeutic interventions have the following options 
to activate sGC and thus increase cGMP synthesis: (1) deliver, in-
crease the synthesis of, or increase the bioavailabilty of NO, (2) de-
liver or increase the synthesis of CO, (3) stabilize the NO or CO ad-
duct,  or  (4)  replace  the  heme  with  something  that  mimicks  the 
heme-nitrosyl complex. To date, there is no therapeutically useful 
way to block the basal activity of the enzyme, but oxidizing the heme 
prevents the activation of sGC by heme ligands which is more than 
sufficient  to achieve an overall  reduction of  cGMP synthesis.  The 
mechanisms of modulating sGC activity are depicted in the context 
of  the  NO/cGMP and CO/cGMP signal  transduction pathways in 
Fig. (1).
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Fig.1: Schematic representation of the signal transduction mediated 
by sGC. NO, nitric oxide; CO, carbon monoxide; NOS, nitric oxide 
synthase;  HO,  heme  oxygenase;  sGC,  soluble  guanylyl  cyclase; 
sGCox, heme-oxidized soluble guanylyl cyclase; GTP, guanosine tri-
phosphate;  cGMP,  cyclic  guanosine  monophosphate;  GMP, 
guanosine monophosphate; PDE, phosphodiesterase. »stimulators«, 
»activators«, and »inhibitors« denote the classes of heme-dependent 
activators, heme-independent activators, and oxidants, respectively, 
which modulate sGC activity.
14
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PATHOLOGIES RELATED TO INAPPROPRIATE 
SYNTHESIS OR EFFECT OF NO AND OF CO
As noted previously, cGMP-mediated signalling plays a crucial role 
in a variety of aspects of the cardiovascular system. Therefore it is 
not suprising to find a number of pathologies related to reduced or 
excess  production  of  NO or  CO,  or  to  a  reduced  effect  of  these 
gaseous  messengers.  Before  moving  on  to  potential  therapeutic 
agents that target sGC, we'll  briefly review the current knowledge 
about some of these diseases with a focus on the role of the cGMP 
signalling pathways in the etiology or in the symptoms.
Atherosclerosis and intimal hyperplasia
The excess proliferation of smooth muscle cells is one of the symp-
toms of atherosclerosis and, somewhat ironically, also a potential 
consequence  of  therapeutic  interventions  intended  to  cure  these 
symptoms, like balloon angioplasty, stenting, and coronary artery 
bypass grafting. Atherosclerosis is a progressive and chronic inflam-
matory response of the vasculature and is the main cause of coron-
ary artery disease [113]. Atherosclerotic lesions are intimal thicken-
ings which consist  of cells,  including blood-bourne immune cells, 
vascular smooth muscle cells, and endothelial cells, as well as an 
accumulation of extracellular matrix, lipids, and debris. The chronic 
consequences of this disease are closely related to the endothelial 
dysfunction that is an early marker of this disease [114], and which 
impairs the release of endogenous vasodilating and antithrombotic 
substances  like  NO and prostacyclin  in  the  affected areas [115]. 
Acute consequences include the complete restriction of blood flow as 
seen in an acute myocardial infarction, either as a consequence of 
an excessive plaque size, or of a thrombus formation due to plaque 
rupture or endothelial erosion. The proliferation of vascular smooth 
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muscle cells (VSMC) has been recognized as one of the key events of 
the development of atherosclerotic lesions [116]. It is generally as-
sumed that cGMP, and thus all sGC-activating mechanisms, have 
an antiproliferative effect on smooth muscle cells, which ascribes a 
key role to an intact NO-generating endothelium in preventing an 
excessive  VSMC proliferation.  However,  this  view has  been  chal-
lenged  by  experiments  using  cGMP-dependent  protein  kinase  I 
knockouts which revealed both pro- and antiproliferative mechan-
isms triggered by cGMP [117]. Furthermore, increasing NOS-3 ex-
pression to increase cGMP levels has not always provided beneficial 
results in terms of the progression of the disease [118]. These res-
ults notwithstanding, there is ample evidence for an antiatherogenic 
role of NO [119] and increasing evidence that CO may play a similar 
role [5,8,120,121].
The development of percutaneous treatments of stenoses using bal-
lon angioplasty or stenting has been a major progress in the treat-
ment of coronary artery disease. However, an estimated 30%-50% of 
all patients undergoing simple angioplasty and 10%-30% of all pa-
tients receiving a stent suffer from restenosis [122,123]. This should 
not be viewed as a recurrence of the underlying vascular disorder, 
but as a consequence of the intervention itself [124,125]. Coronary 
artery bypass grafting with autologous vessels is still the treatment 
of  choice,  especially  for  multivessel  coronary  artery  disease 
[126,122]. However, this treatment may cause a similar neointimal 
formation as well. Differences in the diameter or a compliance mis-
match between the graft and the diseased vessel, as well as flow dis-
turbances at the anastomoses may induce neointima proliferation 
[127,128]. Moreover, if the saphenous vein has to be used as a graft, 
as opposed to one of the arteries, the adaptation of the venous ves-
sel to the arterial circulation induces "vein graft disease" with in-
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creased neointima formation [129-131]. Both NO [125] and CO [132] 
supplementation have been shown to inhibit  neointima formation 
after endothelial injury.
Arterial hypertension
Arterial  hypertension  is  characterized  by  a  chronically  elevated 
blood pressure. The majority of these cases can be classified as es-
sential hypertension as there is no apparent medical cause. Treat-
ment  is  usually  symptomatic  by  blood-pressure  lowering  agents. 
Several animal models were developed to investigate arterial hyper-
tension, with the spontaneously hypertensive rat (SHR) being the 
best  known.  This  model  showed  that  hypertension  is  associated 
with an impairment of endothelium-dependent relaxation and lower 
cGMP contents, suggesting an involvement of the NO/cGMP system 
[133,134].  The  following  major  mechanisms contribute  to  the  re-
duced cGMP synthesis: in the aorta of SHR the release of NO is es-
sentially unaltered [135], but its bioavailability and its effect are de-
creased due to an excess of reactive oxygen species [136-139]. There 
are no major changes in the expression of NOS, whereas the expres-
sion of sGC and other cGMP-regulated proteins is attenuated [140-
142], suggesting a smooth muscle layer dysfunction secondary to 
the endothelial dysfunction.
In  young  SHR a  decreased  expression  of  HO-1 and of  sGC was 
shown, indicating an impairment of the CO/cGMP system in addi-
tion to the NO/cGMP system [143]. Surprisingly, counterregulatory 
mechanisms lead to a normalized cGMP synthesis in response to 
CO. However, the signal transduction downstream of cGMP are ap-
parently attenuated at this stage, leaving the overall CO/cGMP sig-
nal transduction in a dysfunctional state [144]. Interestingly, trans-
genic mice that overexpress HO-1 showed an elevated rather than a 
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reduced blood pressure, arguing against a vasodilatory role of CO in 
the vasculature. sGC expression was not reduced, but the sGC-me-
diated responses to exogenous NO were reduced. These responses 
could be restored by administering the HO inhibitor tin protopor-
phyrin IX. Apparently the excess CO released by HO competes with 
NO for the sGC heme, but causes a far less cGMP production when 
bound [145].
Pulmonary arterial hypertension
In contrast to arterial hypertension which usually manifests itself 
systemically, the blood pressure elevation in pulmonary hyperten-
sion is restricted to the pulmonary circulation and is accompanied 
by vascular remodeling of the lung and by right ventricular hyper-
trophy. Although the etiology of this disease differs from arterial hy-
pertension, the regulatory mechanisms of the endothelium and the 
consequences of endothelial dysfunction are strikingly similar [146-
149]. There is apparently no downregulation of NOS, but in addition 
to  a  reduced bioavailability  of  NO due to  oxidative  stress  an in-
creased level of the endogenous NOS inhibitor asymmetric dimethyl-
arginine (ADMA) may play a crucial role [150]. ADMA does not only 
reduce NO synthesis,  but it  also uncouples the enzyme, allowing 
electron transfer to oxygen instead of to arginine which ultimately 
causes  oxidative  and  nitrosative  stress [151].  Other  contributing 
factors to the uncoupling may be a reduced availability of the sub-
strate arginine due to an excess of arginase [152] and a lack of the 
essential NOS cofactor tetrahydrobiopterin [153].
Inhaled NO was first used in 1991 to reduce the pulmonary vascu-
lar resistance [154]. Due to the mainly local effects of the inhaled 
gas in the well-ventilated areas of the lung there were no systemic 
cardiovascular effects, in contrast to an equieffective i.v. dose of the 
18
Cardiovascular Effects of sGC modulation
vasodilator prostacyclin.  Alternatively, NO-releasing agents can be 
administered as aerosols to achieve a similar local effect [155].
A related syndrome, though again of a different etiology, is pulmon-
ary hypertension of the newborn. The pulmonary circulation under-
goes a remarkable change during birth in order to allow the new-
born to meet her oxygen needs through the lung instead of through 
the placental circulation. The pulmonary vascular resistance has to 
fall within minutes in response to various stimuli during birth [156]. 
Failure to do so is referred to as persistent pulmonary hypertension 
of the newborn (PPHN) and may lead to severe hypoxia and neurolo-
gical disorders. VEGF apparently plays a major role in the onset of 
PPHN as it experimentally causes an NO-mediated vasodilation but 
appears to be suppressed in PPHN [157-159]. Just as with other 
forms of hypertension, NOS uncoupling also seems to be involved 
[160] although a recent report indicates that uncoupling postnatally 
creates reactive oxygen species which act as an endothelium-derived 
hyperpolarizing factor (EDHF) and thus fulfill  a regulatory role in 
the pulmonary circulation of healthy subjects as well [161].
Congestive heart failure
Congestive heart failure (CHF) is characterized by an increased peri-
pheral vascular resistance, which in turn causes an increased after-
load of the heart. CHF is associated with endothelial dysfunction, 
either as a cause or as a consequence. In this setting, a decreased 
expression of NOS in the vasculature may cause an insufficient NO 
synthesis, although a recent study failed to find evidence for this 
[162]. Instead, an increased level of the endogenous NOS inhibitor 
ADMA appears to be present in CHF patients [163]. Oxidative stress, 
partly  due  to  uncoupling  of  NOS [164],  further  decreases  the 
bioavailability of NO. Unfortunately, many CHF patients do not re-
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spond well  to a NO replacement therapy with organic nitrates as 
they show an early onset of nitrate tolerance [165]. One likely reas-
on for this phenomenon is a shift of the equilibrium of ferrous to-
wards ferric heme in sGC due to the increased oxidative stress.
Cardiac myopathy
A variety of vascular disorders cause a hypertrophy of the heart, or 
of parts of the heart, in response to increased pulmonary or system-
ic vascular resistance, or as a consequence of myocardial infarction 
due to coronary artery disease. There appears to be a compensatory 
upregulation of NOS-2 in response to a decreased expression and 
activity  of  NOS-3  in  cardiac  tissue  in  ischemic  cardiomyopathy 
[166,167]. The NO/cGMP system is seen as an important regulatory 
mechanism to prevent hypertrophy [168].
Thrombosis
Increasing the synthesis of cGMP by platelet sGC through NO form-
ation is one of the mechanisms that an intact endothelium employs 
to prevent the aggregation of platelets and a subsequent thrombus 
formation, as reviewed in [169] and in [170]. See also [171] for a full 
list of molecules released by the endothelium which affect platelet 
function. Platelets are also known to synthesize NO themselves. As 
mentioned above, the endothelial NO synthesis is tightly regulated 
by  shear  stress.  Therefore  thrombus formation is  likely  to  occur 
when the blood flow is impaired, e.g. in varicose veins, or if the en-
dothelial production of antithrombotic substances ceases due to en-
dothelial dysfunction. Plaque rupture in an atherosclerotic coronary 
artery  may  induce  a  thrombus  and  thus  cause  unstable  angina 
[172] or even acute myocardial infarction [173]. NO donors display 
antithrombotic effects ex vivo [3] and may thus contribute to prevent 
thrombosis.
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Circulatory shock
Shock is characterized by a vasoplegic and hypotensive state which 
leads to a malperfusion and thus a lack of oxygen. This may ulti-
mately cause a dysfunction of vital organs like the brain, kidney, or 
liver. Several types of shock are distinguished based on the etiology: 
cardiogenic shock (myocardial infarction), hemorrhagic shock (fluid 
or  blood  loss),  septic  shock  (severe  infection),  and  anaphylactic 
shock (severe allergic reaction) [174]. One of the main vasodilators 
whose levels are increased during shock is NO. However, the origin 
of NO is still a matter of debate. Polymorphonuclear leucocytes from 
patients with sepsis  syndrome display  an increased NOS activity 
[175] which is mainly due to an increased NOS-2 expression [176]. 
On the other hand, an analysis in a mouse shock model revealed 
that  the  NO production  during  septic  shock  depends  on  paren-
chymal cells in the liver, kidney, and gut rather than on hematopoi-
etic cells [177].  The expression of NOS-2 is also increased in the 
myocardium during sepsis [178]. Although blocking the NO release 
is a tempting strategy to overcome the hypotension associated with 
shock,  early  attempts  have  shown  a  decrease  in  cardiac  output 
[179] as well as an increased mortality in an animal model [180]. 
This is in part due to a paradox protective effect of NO, e.g. on the 
perfusion of the kidney [174]. An involvement of heme oxygenase in 
the vascular dysfunction during shock is also discussed, as CO ap-
pears to inhibit flow-induced relaxation by inhibiting NOS and by 
competing with NO as a heme ligand of sGC [181].
SOLUBLE GUANYLYL CYCLASE STIMULATORS AND 
ACTIVATORS
The description of the mechanisms of activation of sGC outlined the 
available  strategies  to  elevate  intracellular  cGMP  levels  by  com-
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pounds that directly interact with sGC, or by prodrugs which re-
lease such compounds. The main distinction used here is between 
substances that require the reduced heme moiety to be present in 
sGC and those that activate the oxidized or heme-free form of sGC. 
The former group includes all NO and CO releasing compounds, as 
well as a variety of substances which do not bind to the heme moi-
ety but require its presence. The latter substances have been termed 
somewhat  arbitrarily  "stimulators",  to  distinguish  them from the 
"activators" which activate the oxidized or heme-free enzyme [182].
Drugs targeting reduced and heme-containing sGC
NO and NO- donors
As noted previously, the NO replacement therapy using organic ni-
trates like GTN or isosorbide dinitrate, or the chemically unrelated 
sydnonimines has proven to be beneficial in the treatment of angina 
pectoris for more than a hundred years. Organic nitrates are prod-
rugs which require a biotransformation to NO in order to activate 
sGC. The enzyme responsible for the bioactivation of highly reactive 
nitrates like GTN in the vasculature is the mitochondrial aldehyde 
dehydrogenase  ALDH-2 [183],  whereas  less  potent  nitrates  are 
metabolized differently [184]. Organic nitrates have two major disad-
vantages: (1) nitrate tolerance, which enforces a nitrate-free interval 
per day in order to preserve the antianginal effect for the remainder 
of the time, does not permit a full protection [185] with the notable 
exception of pentaerythrityl tetranitrate [186], and (2) the metabol-
ism of  organic  nitrates causes oxidative  stress which further de-
creases the effect of the drugs [187]. A "primary" nitrate tolerance 
may be a consequence of NO resistance due to smooth muscle dys-
function (see above), whereas a "secondary" tolerance is induced by 
continuous use and includes a decreased bioactivation of the ni-
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trates [188]. The current status of the NO replacement therapy has 
been reviewed elsewhere [14,189-191]. The treatment of lung dis-
eases with inhaled NO was also covered by a recent review [192]. In 
order to provide more room for novel strategies in the present re-
view, the reader is referred to these excellent overviews.
YC-1
Since the description of its antiplatelet activity [94], YC-1 has been 
tested in a variety of settings for its cardiovascular and other effects. 
YC-1 has well-established vasorelaxing properties on its own, and it 
potentiates the relaxation induced by various NO donors [97]. How-
ever, it should be kept in mind that sGC is not the only target for 
YC-1.  For  example,  YC-1  is  known  to  inhibit  phosphodiesterase 
isoenzymes 1 through 5 [193], which allows some cellular effects of 
YC-1 to be mediated by cAMP rather than by cGMP [194], to relax 
vessels  partially  through an activation of  large conductance  BK
Ca 
channels [195,196],  to  induce  NO  release  from  endothelial  cells 
[197], to relax human mesenteric artery partly by activating sodium 
pumps [198], to protect white matter axons from nitrosative stress 
through sodium channel inhibition [199], and to cause a vasocon-
striction in isolated vessels of coronary artery bypass patients [200]. 
Further effects of YC-1 have been summarized recently [201]. This 
section focuses on those cardiovascular effects of YC-1 which are 
mediated by sGC, or where an sGC-mediated mechanism has been 
discussed. The chemical structures of YC-1 and of other heme-de-
pendent modulators are shown in Fig. (2).
A study comparing newborn and 2-week old piglets revealed that the 
sensitivity of pulmonary arteries towards YC-1 is developmentally 
regulated in that YC-1 is more potent in 2-week old piglets. The re-
laxing effect of YC-1 depended on the presence of the endothelium 
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in 2-week old piglets, indicating that endogenous NO release con-
tributes to the stronger effect of YC-1 in these vessels. Exogenous 
NO also induced a stronger relaxation in the older vessels, and this 
effect was potentiated by YC-1 only in these vessels. [202]. These 
results indicate that sensitizing sGC may not be a suitable approach 
to treat PPHN.
O'Reilly et al.   [203]  tested whether YC-1 at least partially restores 
the vasorelaxing effects of organic nitrates even in a state of toler-
ance. 3 µM YC-1, which by itself did not relax GTN-tolerant rabbit 
aortic rings, caused a 6-fold increase of the potency of GTN, thus 
restoring most of the responsiveness lost due to tolerance.
Perioperative radial artery graft vasospasm is a well-known complic-
ation of coronary artery bypass grafting and may cause early graft 
failure. Several substances have been commonly used to relax the 
grafts  during  surgery,  like  phenoxybenzamine,  GTN/verapamil, 
papaverine,  and  others [204].  Ideally,  the  spasmolytic  effect  of  a 
substance should last into the postoperative period to provide best 
possible protection. Of the substances mentioned above, only phen-
oxybenzamine (a nonspecific α-adrenoceptor antagonist which binds 
covalently) provides at least 24h protection under clinical conditions 
(i.e. incubation time approx. 15min). The spasmolytic properties of 
YC-1 for CBG were compared to the NO donor 2-(N,N-diethylamino)-
diazenolate-2-oxide (DEA NONOate) [205]. Although the EC
50
 for YC-
1 was higher, the same maximum relaxation was achieved with both 
vasodilators. In contrast to DEA NONOate, the relaxing effect of YC-
1 could not be completely blocked by ODQ, but with a combination 
of ODQ and the potassium channel blocker iberiotoxin, indicating 
that the relaxing effect of YC-1 is partially due to an interaction with 
potassium channels. Unfortunately, the duration of the spasmolytic 
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action was not investigated in this study, but due to its hydrophobic 
nature the action is likely to last sufficiently long to be clinically 
useful. To date, the metabolism of YC-1, which may also limit its 
duration of action, has not been investigated in vascular tissue.
Hypertension is associated with a decreased bioavailability of NO. 
One proposed approach to restore vascular function is to enhance 
the effect of the remaining NO, or to activate sGC independent of 
NO. In a mouse model of hypertension induced by inhibition of NOS, 
YC-1 was shown to retain its vasorelaxing effect completely. Both 
the EC
50
 values and the maximum effect were unaltered in hyper-
tensive mice compared to the controls [139]. These data confirm an 
earlier study performed in a similar rat model of hypertension [206]. 
These studies indicate that YC-1 is a useful vasodilator to reduce 
blood pressure in hypertension, either used alone or in conjunction 
with a NO donor. However, these results must be interpreted with 
care as these models may not properly reflect the smooth muscle 
dysfunction found in SHR [141,142].
The influence of YC-1 on the amount of neointima formed after bal-
loon angioplasty was investigated in a rat model. YC-1 was applied 
as a hydrogel to the damaged site immediately after removing the 
catheter. The histological evaluation of vessel cross sections after 2 
weeks showed a reduction of neointima formation by YC-1 in terms 
of neointima area (-74%),  ratio neointima and media wall  (-72%), 
and neointima thickness (-76%) [207]. The authors further showed 
in an VSMC cell culture model that YC-1 embedded in a hydrogel 
inhibited proliferation without adverse effects on viability. Moreover, 
platelet aggregation and adhesion to collagen were reduced by YC-1 
gel as well [208]. Thus, YC-1 applied locally after balloon angioplasty 
has a dual vasoprotective effect at the damaged site. An involvement 
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of  CO released by  heme oxygenase  is  discussed  but  not  directly 
shown. The authors reason that the NO synthesis is greatly reduced 
by the damage to the endothelium whereas HO expression is in-
creased as a compensatory mechanism which can further be en-
hanced by YC-1. However, when applying YC-1 orally after balloon 
angioplasty in rats, the affected vessels did not show elevated cGMP 
contents, although a similar degree in neointima reduction was seen 
[209]. An analysis of the expression and the activity of the metallo-
proteinases MMP-2 and MMP-9, which are involved in the synthesis 
and restructuring of  extracellular  matrix,  revealed that  these  are 
upregulated and more active after the angioplasty. YC-1 prevented 
this  upregulation,  and had a direct  inhibitory  effect  on both en-
zymes with IC
50
 values in the micromolar range. Therefore it seems 
unlikely that the inhibition of neointima formation by YC-1 is medi-
ated via sGC.
BAY 41-2272, BAY 41-8543, and BAY 63-2521
BAY 41-2272 and the closely related BAY 41-8543 are the first of a 
series of YC-1 analogs that found widespread use as a research tool 
as well as testing in animal models. The history of the discovery of 
these  and  some  related  substances  has  been  reviewed  recently 
[182]. While based on the same molecular structure as YC-1, both 
BAY 41-2272 and BAY 41-8543 are about two orders of magnitude 
more potent at stimulating isolated sGC than the parent compound 
[100,210]. Although this might give BAY 41-2272 an edge over YC-1 
also in terms of specificity for sGC activation, there is some evidence 
that the former also has cellular targets other than sGC. Similar to 
YC-1, BAY 41-2272 was found to inhibit PDE5 [211], but these ex-
periments used a concentration of 200µM, which is at least 1000-
fold higher than the concentration thought to cause a biologically 
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relevant elevation of cGMP through sGC activation [100,212]. Recent 
data  suggest  that  vasodilation  induced  by  BAY 41-2272  may be 
caused in part by a direct stimulation of the sarcolemmal sodium 
pump in ovine pulmonary artery [213], whereas in rat basilar artery 
the effect of BAY 41-2272 on the sodium pump was apparently me-
diated by cGMP [214] and thus remains controversial for the time 
being.
Both BAY 41-8543 and BAY 41-2272 exhibit long-lasting vasodilat-
ory actions although both compounds are rapidly oxidized in vivo. 
However, the main metabolites of these substances act as sGC-tar-
geted vasodilators as well, explaining the long-lasting effect [215]. 
Both substances also exhibit antiplatelet effects [216,210].
BAY 41-8543 was shown to relax rabbit aortas, rabbit saphenous 
arteries, porcine coronary arteries, and canine femoral vein with a 
similar or higher potency than SNP, 3-morpholinosydnonimine (SIN-
1), and GTN [210]. In a rat Langendorff heart, the substance caused 
a  drop  in  coronary  perfusion  pressure  without  affecting  left 
ventricular pressure or heart rate. The substance has also a marked 
antiplatelet effect ex vivo. BAY 41-8543 had a blood-pressure lower-
ing effect in normotensive rats and dogs as well as in SHR [217]. In 
contrast to YC-1, BAY 41-8543 lowered the blood pressure even if 
applied orally.
BAY 41-2272 relaxes both endothelium-intact and denuded rabbit 
aorta [218]. Denuding increased the EC
50
 significantly, and the NOS 
inhibitor N
G
-Nitro-L-arginine-methyl ester (L-NAME) shifted the BAY 
41-2272 dose-response curve to the right in intact vessels, indicat-
ing that a part of the relaxing effect of BAY 41-2272 in intact vessels 
is due to a synergism with endogenously released NO. The maxim-
um relaxing response was not affected by denuding.
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Several studies evaluated the possible beneficial effects of BAY 41-
2272 in various models of hypertension. Transgenic mice carrying 
an additional copy of the renin gene react to the administration of L-
NAME with a marked increase of systolic blood pressure due to a 
lower basal NO synthesis. BAY 41-8543 prevented this increase of 
the blood pressure, and allowed all treated animals to survive after 
5 weeks, whereas in the control  group 9 out of  14 animals died 
[217].  BAY  41-2272  was  equally  effective  in  the  same  model. 
Moreover, this salutary effect persisted over 6 weeks without any 
signs of tolerance, and caused a marked decrease in mortality (2 
dead animals out of 20, compared to 13 out of 19 in the control 
group) [100].  In  angiotensin  II-induced  hypertension  in  rats,  a 
10mg/kg per day dose of BAY 41-2272 partially inhibited the rise in 
blood pressure [219]. BAY 41-2272 significantly reduced the hyper-
tension-induced increase in heart weight and positively influenced 
several other parameters of cardiac remodeling. The substance has 
a similar beneficial effect in a rat hypertension model induced by 
chronic administration of the NOS inhibitor L-NAME [220].
Boerrigter et al. compared the effect of BAY 41-2272 to GTN in a 
canine model of CHF [221]. BAY 41-2272 acted as an arterial vas-
odilator and reduced mean arterial pressure and pulmonary artery 
pressure. Both systemic and renal vascular resistance were lowered. 
In contrast to GTN, BAY 41-2272 did not affect right atrial pressure 
or  pulmonary  vascular  resistance.  Therefore,  BAY  41-2272  acts 
solely as an arterial dilator, in contrast to GTN which is biotrans-
formed mainly in the venous system. Furthermore BAY 41-2272 re-
duced pulmonary capillary wedge pressure, increased cardiac out-
put, and increased renal blood flow. Both the cardiovascular and 
renoprotective  effects  of  BAY  41-2272  seem to  be  useful  for  the 
treatment of CHF.
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In a lamb model of pulmonary hypertension induced by a thrombox-
ane A
2
 analog, low intravenous doses of BAY 41-2272 allowed to se-
lectively reduce mean pulmonary arterial pressure and pulmonary 
vascular resistance without eliciting a systemic vasodilation [222]. 
BAY 41-2272 also potentiated the effect of inhaled NO, whereas in-
haled CO did not affect the pulmonary vasoconstriction even in the 
presence of BAY 41-2272. The capacity of this substance to prevent 
or reverse pulmonary vascular remodeling was also tested in a study 
involving two rat models: (1) NOS-3 knockout mice and wild-type 
mice as a control group which both were subjected to chronic hyp-
oxia, and (2) rats which received monocrotaline [223]. BAY 41-2272 
reversed pulmonary hypertension, right heart hypertrophy, and pul-
monary vascular remodeling in the wild-type mice and the mono-
crotaline-treated rats, but not in the knockout mice. The authors 
concluded that the beneficial effect of BAY 41-2272 in the treatment 
of pulmonary hypertension is partly dependent on endothelial NO 
release. In another report using hypoxia to induce pulmonary hy-
pertension, Deruelle et al.   [224]  described that BAY 41-2272 preven-
ted right ventricular hypertrophy and an hypoxia-induced increase 
in arterial  wall  thickness.  The  antihypertensive  effect  of  BAY 41-
2272 was also shown recently in a canine model of pulmonary hy-
pertension using the interaction of heparin and protamine to induce 
the condition [225]. Finally, both BAY 41-2272 and BAY 41-8543 
were shown to cause pulmonary vasodilation in lambs when inhaled 
as microparticles [226].
BAY 41-2272 was also found to  be  effective  in a ovine  model  of 
PPHN [227]. The substance reduced pulmonary vascular resistance 
and increased pulmonary blood flow by a sustained pulmonary vas-
odilation. Interestingly, the effect of BAY 41-2272 was not affected 
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by  the  NOS inhibitor  N
G
-nitro-L-arginine,  suggesting  that  in  this 
model the effect of BAY 41-2272 did not depend on endothelial NO 
release.
BAY 63-2521, another heme-dependent sGC stimulator, was applied 
to patients suffering from moderate to severe pulmonary hyperten-
sion. The substance improved the main hemodynamic parameters, 
proved to be more effective than inhaled NO, and did not cause seri-
ous adverse events [228].
CFM1571
Another effort at compound screening resulted in the development 
of CFM1571 and a couple of related substances [229]. All of these 
are benzydamine analogs and are thus structurally related to YC-1. 
Benzydamine itself is an antiinflammatory and analgesic compound 
whose mechanism of action is not well understood [230]. The au-
thors investigated the capacity of various modifications of the parent 
compound to enhance the activation of partially purified sGC in the 
presence of a submaximally activating dose of the NO donor DEA 
NONOate. The substances which showed an improved sGC activa-
tion compared to the parent compound were further tested for their 
antiplatelet effect,  and were subjected to further tests in order to 
elucidate possible interactions with other enzymes of the NO/cGMP 
system. CFM1571 was finally selected as a stimulator of heme-con-
taining sGC, without PDE inhibitor activity, with minor inhibition of 
NOS-3 and an acceptable bioavailability of 12%. Unfortunately there 
are no comparisons with other sGC stimulators available to date, 
which makes it difficult to fully appreciate the potential of this com-
pound.
A-350619
A-350619 is another heme-dependent stimulator of sGC, but this 
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substance is structurally not related to YC-1 [231]. A-350619 appar-
ently uses the same binding site as YC-1 as their effects on sGC 
activity are not additive. In the absence of NO, both A-350619 and 
YC-1 induced a 70-fold activation. In the presence of SNP, YC-1 and 
A-350619 activated the enzyme 160-fold and 230-fold, respectively. 
A-350619 showed a more pronounced effect both on v
max
 and K
m 
compared  to  YC-1.  The  substance  induced a  dose-dependent  in-
crease of cGMP levels in smooth muscle cells,  and relaxed rabbit 
corpus cavernosum strips.
A-778935
(±)-cis-3-[2-(2,2-dimethyl-propylsulfanyl)-pyridin-3-yl]-N-(3-hydroxy-
cyclohexyl)-acrylamide (A-778935) is also based on a structure un-
related to YC-1 or any of the other known stimulators of sGC. The 
substance activated sGC in a synergistic fashion with the NO donor 
SNP, achieving an up to 420-fold activation [232]. The activation by 
A-778935 could be blocked by ODQ and was strictly dependent on 
the  presence  of  heme.  The  substance  increased  cGMP  levels  in 
smooth  muscle  cultures  and  relaxed  rabbit  corpus  cavernosum 
strips. Both effects were further enhanced by SNP.
CO and CO donor drugs
The  role  of  CO in  cardiovascular  function has been reviewed re-
cently [233]. Again, the following discussion focuses on those effects 
of CO which are thought to be mediated by sGC. In contrast to the 
multitude of NO-releasing agents, the number of ways to deliver CO 
(besides inhaling the gas) are fairly limited. The best known mem-
bers of CO releasing agents belong to a group of transition metal 
carbonyls  which  were  reviewed recently [234,235].  The  first  of  a 
series of aptly named substances (CORM = CO Releasing Molecule), 
CORM-1  and  CORM-2,  were  limited  by  their  low  solubility  in 
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aqueous  media.  The  newer  substances 
tricarbonylchloro(glycinato)ruthenium(II) (CORM-3) and sodium bor-
anocarbonate (CORM-A1) are water-soluble. The latter contains the 
metalloid  boron  instead  of  a  transition  metal.  These  substances 
mainly differ in the mode and speed of CO release. CORM-3 has a 
half-life in aqueous solutions of approx. 1min, whereas the CO re-
lease from CORM-A1 is approx. 20 times slower.
The CORM-3 induced relaxation of rat aorta was both inhibited by 
the  sGC  inhibitor  ODQ  and  by  the  potassium  channel  blocker 
glibenclamide, indicating a dual relaxing mechanism [236]. YC-1 at 
a concentration of 1µM, which did not have a relaxing effect on its 
own, further enhanced the relaxing effect of CORM-3. The adminis-
tration of CORM-3 increased the cGMP levels in the vessels. Inter-
estingly, the relaxing action of low (100µM) doses of CORM-3 de-
pended on a functional NOS, as both the removal of the endotheli-
um and NOS inhibition abolished the relaxing effect  of  this dose 
(higher doses still relaxed though). The authors also investigated the 
effect of CORM-3 infusions on the mean arterial blood pressure in 
rats. CORM-3 reduced the MAP significantly, but even stronger so in 
the presence of YC-1. These data indicate that a CO releasing mo-
lecule has profound vasodilating properties in vitro and in vivo, and 
that a major part of this effect is brought about by sGC activation. 
CORM-A1  caused  a  slower,  but  stronger  relaxation  of  rat  aortic 
rings  compared  to  CORM-3.  This  relaxation  was  dose-dependent 
and could be inhibited by myoglobin, a known CO scavenger, and 
by ODQ [234]. Neither NOS inhibition nor potassium channel block-
ing affected the relaxation by CORM-3, indicating that in contrast to 
CORM-3 the vasodilatory effect is entirely mediated by sGC. There 
was also an enhancement of the relaxation by concomitant infusion 
of a low dose of YC-1. CORM-A1 also induced a slow decrease of 
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MAP in rats. Simultaneous administration of YC-1 both sped up and 
intensified the pressure drop.
Musameh et al.   [237]  showed an intersting differential effect of two 
CO donors on isolated perfused rat hearts,  testing both constant 
coronary flow and constant coronary pressure. CORM-3 showed a 
direct positive inotropic effect with a slight reduction in heart rate in 
both settings, but did not affect coronary flow. CORM-A1, which re-
leases CO slower than CORM-3, dilated the coronary vessels signi-
ficantly without affecting the heart rate or contractility. The effects 
of CORM-3 were affected by inhibitors of sGC and of the sodium 
pump, but not by an inhibitor of calcium channels.
CORM-3 has also been reported to inhibit platelet aggregation. In 
contrast to the vascular effects described above, the antiplatelet ef-
fect  appeared to  be  mediated by a sGC-independent  mechanism. 
The  sGC  inhibitor  ODQ further  enhanced  the  antiplatelet  effect, 
whereas YC-1 failed to do so [238].
Boissiere et al.   [239]  investigated the relaxing effect of CORM-2 on 
aortas obtained from normotensive rats and from rats made hyper-
tensive by the Goldblatt procedure. CORM-2 relaxed the aortas of 
the rats independent of the level of physical exercise. However, pre-
vious exercise left the aorta of hypertensive animals even more re-
sponsive to CORM-2 than the normotensive controls, whereas exer-
cise had no effect in the latter. Pretreatment of the vessel rings with 
the potassium channel blockers iberiotoxin or tetraethylammonium 
abolished the differences between the sedentary and exercise hyper-
tensive groups, without abolishing the relaxing effect of CORM-2 en-
tirely. This indicates that the CO/sGC pathway is apparently unaf-
fected by physical exercise, whereas the vasodilatory action medi-
ated by potassium channels is modified.
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The irontricarbonyl complexes CORM-F3, CORM-F7, CORM-F8 and 
CORM-F11  are  members  of  a  new  class  of  CO  releasing  agents 
[240,241]. Of these, CORM-F3 showed the highest CO release and 
the lowest cytotoxicity. The substance was able to relax rat aortic 
rings, but it was not further investigated whether the mechanism of 
action involved sGC.
With CO being a  gas,  inhalation of  sublethal  doses  is  a  feasible 
route of administration. Several studies have investigated the cardi-
ovascular effect of inhaled CO, some of which have been shown to, 
or are likely to, be mediated by sGC activation. In a rat transplant 
model, Otterbein et al.   [5]  were able to show that atherosclerotic le-
sions induced by chronic graft rejection were suppressed by CO in-
halation during the postoperative period of the experiment (56 days). 
In rat carotid arteries subjected to balloon dilatation, a one-hour in-
halation of CO before the procedure suppressed neointimal hyper-
plasia as well. The antiproliferative effect of CO in smooth muscle 
cell cultures was blocked by the sGC inhibitor ODQ and would be 
mimicked by the non-hydrolyzable cGMP analog 8-Br-cGMP. A sim-
ilar vasoprotective effect of CO in balloon-dilated vessels was also 
shown in Yorkshire pigs [242]. Finally, Ramlawi et al.   [243]  showed 
in the same species that a single 1h-exposure to inhaled CO periop-
eratively prevents intimal hyperplasia on the venous side of an ar-
teriovenous PTFE graft.
Other drugs
The laboratory that described the antiplatelet effects of YC-1 in 1994 
[94] characterized a number of derivatives of YC-1, which provided 
some insight into the structure-activity relationships of this class of 
molecules [244]. Although none of these derivatives activated sGC 
more potently than YC-1, some turned out to be more potent PDE5 
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inhibitors. Another series of YC-1 derivatives yielded several com-
pounds with antiaggregating effects, but none of them was found to 
activate sGC [245]. 3-(3[1,2,4]triazolo)-oxatriazolium-5-olate (AS-6), 
a member of a class of substances that have long been known for 
their  hypotensive  action in animals [246],  was shown to activate 
isolated porcine lung sGC 29-fold.  The activation was further en-
hanced twofold by YC-1 and blocked by ODQ [247]. The substance 
was shown to decrease the perfusion pressure of an isolated rat tail 
artery by up to 26%. The protoporphyrin IX derivates 2,4-di(1-meth-
oxyethyl)-deuteroporphyrin  IX  (dimegin)  and  hematoporphyrin  IX 
(HP) were found to activate sGC in human platelet cytosolic frac-
tions 3.2-fold and 2.7-fold, respectively [248]. The mechanism of ac-
tivation of these substances is currently still unclear as it was re-
ported to be synergistic with NO, which would require the heme of 
sGC to be present instead of being replaced by one of these analogs, 
as the latter lack an iron for NO to interact with. Due to the limita-
tions of the test system, the results may be explained by assuming a 
mixture of heme-containing and heme-deficient sGC, with NO acting 
on the former and the heme analogs on the latter.
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Fig. 2: Chemical structures of heme-dependent sGC stimulators and 
of CO-releasing molecules (CORM-3, CORM-A1).
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Drugs targeting oxidized and heme-free sGC
As  mentioned  previously,  oxidative  stress  and  the  resulting  de-
creased bioavailability of endogenous NO are a common feature of 
diseases which are caused by, or are accompanied by endothelial 
dysfunction. Late-stage atherosclerosis has been shown to result in 
a type of vascular dysfunction which not only impairs the function 
of the endothelium, but also of the smooth muscle layer. Melichar et 
al.   [249]  found  a  decreased  sGC  expression  and  activity  in  the 
neointimal layer sGC along with a lower expression of some of the 
downstream  proteins  of  the  cGMP  signalling  pathway,  whereas 
Francois et al.   [250]  actually found an overexpression of dysfunc-
tional sGC in a similar hypercholesterolemic rabbit model. The res-
ulting phenotype was dubbed "NO resistance syndrome" [251]. The 
dysfunctional  sGC  seen  in  these  models  was  later  shown  to  be 
identical  with  heme-free  sGC  or  sGC  containing  oxidized  heme 
[252]. Obviously, the affected vessels are no longer accessible to a 
classical NO replacement therapy or a therapy with the above men-
tioned  heme-dependent  sGC  stimulators.  However,  in  the  past 
couple of years a small but growing number of sGC activators were 
discovered which possess the unique ability to activate heme-free or 
oxidized sGC and thus selectively target the areas affected by the 
NO resistance  syndrome.  The  chemical  structures  of  these  sub-
stances are shown in Fig. (3).
BAY 58-2667
BAY 58-2667 was another substance found in a high throughput 
screening effort [111]. In contrast to stimulators like YC-1 or BAY 
41-2272, the activation of purified sGC by this novel substance was 
actually enhanced, rather than blocked, by ODQ. Along the same 
lines,  purified sGC rendered heme-free by detergent pretreatment 
was activated up to  200-fold.  The  group also  compared the  vas-
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odilatory effect of BAY 58-2667 on isolated rabbit saphenous arter-
ies taken from nitrate-tolerant and control animals. The substance 
turned out to be two orders of magnitude more potent than BAY 41-
2272, and about three orders of magnitude more potent than the 
NO donors SNP and SIN-1 in control animals. Furthermore, the vas-
odilatory response was not affected by nitrate tolerance. BAY 58-
2667 showed antiplatelet effects both in an ex-vivo model and in the 
rat tail bleeding time model. In anesthesized dogs, BAY 58-2667 po-
tently decreased mean arterial pressure, diastolic pulmonary artery 
pressure, and mean right atrial pressure, while showing a longer 
lasting action than an equipotent dose of GTN. In a later study, BAY 
58-2667 was also shown to relax human mesocolon specimens of 
type 2 diabetic patients more effectively than those of control pa-
tients [252]. Using the transgenic renin rat model, the authors were 
able to show that long-term treatment with BAY 58-2667 caused a 
slight decrease in systolic blood pressure, in contrast to the controls 
which developed a noticeable hypertension. While all of the BAY 58-
2667 treated animals survived, 9 out of 20 control animals had died 
at the endpoint of the study.
Three recently published studies assessed the effect of BAY 58-2667 
in disease models of pulmonary hypertension and of heart failure. 
Using both hypoxia-induced and monocrotaline-induced models of 
hypertension, the intravenously administered substance proved to 
be as effective as BAY 41-2272 in reverting the increase in pulmon-
ary artery blood pressure, the right ventricular hypertrophy, and the 
structural remodeling of the lung vasculature [223]. This study also 
showed that in NOS-3 knockouts the beneficial  effect of the sub-
stances was reduced, indicating that endothelial NO is required for 
a full protection. BAY 58-2667 inhaled as microparticles proved to 
be as effective as two sGC stimulators in eliciting a pulmonary vas-
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odilation in lambs [226]. Finally, Boerrigter et al.   [253]  induced CHF 
in mongrel dogs by tachypacing at 240 bpm for several days. Upon 
administering BAY 58-2667, the group found an improved cardiac 
output,  accompanied by a significant  drop in mean arterial,  pul-
monary artery,  right  atrial,  and pulmonary wedge pressures.  The 
latter two parameters indicate that BAY 58-2667 also acts as a ven-
ous dilator, in contrast to BAY 41-2272 which is solely an arterial 
dilator [221]. In addition the renal blood flow increased while the 
renal  perfusion  pressure  decreased.  The  levels  of  the  natriuretic 
peptides ANP and BNP decreased, suggesting an effective unloading 
of the heart.
Patients with acute decompensated heart failure were given BAY 58-
2667 in 2h intervals for up to 6h. The substance induced potent ar-
terial and venous vasodilation, resulting in a noticeable drop of pul-
monary  capillary  wedge pressure  and reductions of  both preload 
and afterload. Only one out of 33 patients reported an adverse event 
[254].
HMR1766, S3448
Two closely related anthranilic acid derivatives, HMR1766 (sugges-
ted name: ataciguat sodium) and S3448 were also shown to activate 
sGC with the same characteristics as BAY 58-2667 [255]. However, 
as the EC
50
 values of sGC activation were calculated as 0,51µM and 
0,68µM, respectively, these compounds are about 50 times less po-
tent than BAY 58-2667. In cultured smooth muscle cells, HMR1766 
induced a dose-dependent increase in cGMP levels which was fur-
ther enhanced by ODQ. The vasodilatory effect was investigated in 
thoracic aortas of rats and of pigs. Both vessels were completely re-
laxed by 30µM S3448, and there was no tachyphylaxis after an 1h 
pretreatment. In anesthesized pigs, HMR1766 caused a long-lasting 
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decrease in systolic blood pressure which was further potentiated by 
simultaneous administration of ODQ. The heart rate was unaffected 
except a slight increase during the peak hypotensive effect.
van Eickels et al.   [256]  investigated salutary effects of HMR1766 in 
a mouse model of atherosclerosis. Although the substance did not 
affect the blood pressure at the endpoint of the study, it significantly 
reduced plaque formation and improved the endothelium-dependent 
vasodilation. Spontaneously hypertensive rats showed improved en-
dothelial  function  in  the  isolated  aorta  and a  prolonged  lifespan 
after HMR1766 treatment starting at 15 months [257]. In a diabetic 
rat model chronic treatment with HMR1766 reduced ex-vivo platelet 
adhesion and in vivo vasodilator-stimulated phosphoprotein (VASP) 
phosphorylation, indicating antithrombotic effects of the substance 
in  the  treatment  of  endothelial  dysfunction  caused  by  diabetes 
[258].
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Fig. 3: Chemical structures of heme-independent sGC activators.
SOLUBLE GUANYLYL CYCLASE INHIBITORS
Just as a decreased bioavailability of NO may be overcome by an ac-
tivation of sGC, an inhibition of sGC may prove useful in cases of 
excess NO production as an alternative to NOS inhibition [259] and 
to NO scavenging [260]. The discussion of the mechanism of sGC 
activation presented the oxidation or removal of the heme moiety as 
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one obvious way to reduce the overall cGMP synthesis. A variety of 
substances, some of which have been in use far longer than their 
mechanism of action was known, oxidize the heme of sGC with reas-
onable specificity to be useful as probes or in the treatment of vas-
cular diseases. Their structures are shown in Fig. (4).
Methylene blue is best known for its use in the treatment of meth-
emoglobinemia, as it activates the enzyme diaphorase II which is re-
sponsible for reducing methemoglobin to the oxygen carrier hemo-
globin [261]. It is also an effective treatment in some forms of priap-
ism [262] which is thought to be due at least in part to its inhibitory 
action on sGC [263], a feature which it shares with the compound 
LY83583 [264]. Both methylene blue [265-267] and LY83583 [265] 
inhibit NOS which also contributes to the cGMP-lowering effect of 
these substances. LY83583 has also been shown to uncouple NOS, 
leading to superoxide generation [268]. The oxidative action of both 
compounds is apparently due to the generation of hydroxyl radicals 
[88]. Methylene blue was further shown to activate potassium chan-
nels [269] which explains a part of its vascular effects.
In a rabbit model of anaphylactic shock induced by C48/80, Buzato 
et al.   [270]  showed that methylene blue infusion reverted the hypo-
tension and significantly prolonged survival of the animals. In aorta 
segments  retrieved  from the  animals  after  the  study  no signs of 
impairment  of  endothelium-dependent  vasorelaxation were  found. 
The same group also found methylene blue to be effective in the 
treatment of a small number of patients suffering from anaphylactic 
shock [271]. The usage of methylene blue in the treatment of septic 
shock has been reviewed recently [272], concluding that in spite of 
well-proven effects on the hemodynamics an improvement of oxygen 
delivery and of mortality has not been studied sufficiently.
ODQ has initially been described as a specific inhibitor of sGC [90] 
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which acts by oxidizing the heme moiety [89]. However, later ana-
lyses pointed out that ODQ interacts with a variety of other heme 
proteins  including  NOS [273].  Zingarelli  et  al.   [274]  showed in a 
murine model of LPS-induced sepsis that ODQ given before or as 
late as 4h after LPS treatment significantly improved the survival 
rates. In isolated rat aortic rings exposed to LPS for several hours, 
ODQ was able to prevent (if given at the same time) or to reverse (if 
given 3h after the LPS treatment) the loss of vascular tone.
NS 2028 also appears to inhibit sGC by oxidizing the heme moiety. 
The substance was shown to constrict porcine coronary arteries and 
to shift the dose-response-curves of the vasodilators GTN and SNP 
to the right [91]. To date, the effect of NS 2028 in vasoplegic states 
has apparently not been studied.
A variety of other sGC inhibitors, such as N-methylhydroxylamine 
[93], carnosine [275], streptonigrin [276], artemisinin [277], and am-
broxol [278], have been described. No cardiovascular effects of the 
former that might involve sGC signalling have been reported to date, 
whereas ambroxol does act as a vasoconstrictor. However, the pos-
sible role of sGC inhibition has not been assessed [279].
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Fig. 4: Chemical structures of heme oxidants of sGC (inhibitors).
ENDOGENOUS MODULATORS OF SGC ACTIVITY
Besides the endogenous substances NO and CO, the heme content 
of cells appears to influence the activity of sGC. Mingone et al.   [280]  
reported that the ratio of δ-aminolaevulinic acid (a heme precursor) 
and iron supplementation in organ culture of endothelium-denuded 
bovine pulmonary artery controlled the ratio of protoporphyrin IX 
and heme, which in turn affected the contractile force in an organ 
bath. After the discovery of new heme-dependent stimulators of sGC 
the question arose whether there are endogenous analogs of these 
substances that further modulate NO or CO signalling. The exist-
ence  of  such  substances  was  primarily  postulated  to  lend  more 
credibility to the CO hypothesis of signalling, as the sGC activation 
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and vasorelaxation elicited by CO alone was thought too low to be of 
relevance compared to NO [281]. Interestingly, in some systems like 
ventricular myocytes CO induces a stronger increase in intracellular 
cGMP levels than equimolar doses of the NO donor SIN-1 or of lig-
ands of particulate guanylyl cyclases [282]. Still there is no conclus-
ive evidence for an "endogenous YC-1" to date.
This does not exclude the possibility that additional mechanisms af-
fect the activity of sGC in vivo.  Suzuki et al.   [283]  investigated the 
inhibitory effect of various organic phosphates on the activity of pur-
ified  sGC.  ATP,  2,3-bisphosphoglyceric  acid,  and  inositol  hexaki-
sphosphate  were  found to  be  competitive  inhibitors  of  the  cGMP 
synthesis of sGC, thus affecting the basal as well as the stimulated 
activity of sGC. This is in contrast to the heme-oxidizing inhibitors 
mentioned above which do not affect the basal activity. ATP showed 
an additional non-competitive regulatory effect at high concentra-
tions. Inhibition by ATP in vivo would directly link sGC activity to 
the metabolic state of a cell. Cardiolipin, whose involvement in the 
regulation  of  vasospasms  is  suspected,  also  inhibited  sGC basal 
activity in this study.
Biliverdin IX is one of the products of the HO catalyzed CO synthes-
is. Biliverdin IX was shown to inhibit both basal and NO-stimulated 
sGC activity by reducing v
max
 without affecting K
m
 [284], providing a 
crosstalk between HO and NO/cGMP signalling.
Finally, several proteins have been shown to modulate sGC activity 
by a direct protein-protein interaction. Geldanamycin, a HSP90 in-
hibitor, reduced NO-stimulated cGMP synthesis in bovine aortic en-
dothelial cells, without affecting the basal cGMP synthesis. A direct 
interaction of HSP90 with the sGC protein was shown by coimmun-
oprecipitation and by the demonstration of  their  colocalization in 
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bovine aortic endothelial  cells and rat  aorta smooth muscle  cells 
[285]. HSP70 was also shown to interact with sGC on a protein level 
using the same techniques, and it increased both the basal and the 
NO-stimulated sGC activity [286]. Finally, the chaperonin contain-
ing t-complex polypeptide (CCT) subunit ν also coprecipitated and 
colocalized with sGC in rat brains. The purified protein decreased 
the NO-stimulated sGC activity to approx. 50% [287]. To date, no 
therapies targeted at or resembling these endogenous modulators 
have been suggested.
CONCLUSION
Substances like GTN have been in use for decades and still provide 
relief from anginal pain for a vast number of patients. There is also 
continued progress in the development of novel NO releasing agents, 
although this was beyond the scope of the present review. The past 
couple of years saw an enormous progress in the development of 
therapeutical  agents targeting sGC which go beyond NO replace-
ment therapy. A variety of heme-dependent sGC stimulators allow to 
enhance the cGMP synthesis in the target cells to normal levels in 
spite of a reduced NO production or bioavailability caused by en-
dothelial  dysfunction.  Animal  models  of  hypertension,  congestive 
heart failure, nitrate tolerance, pulmonary hypertension, and per-
sistent pulmonary hypertension of the newborn as well as a prelim-
inary  study  with patients suffering  from pulmonary hypertension 
have demonstrated the versatility and usefulness of this therapeut-
ical approach. In addition, a couple of CO-related strategies have 
emerged. Both CO inhalation and a variety of CO donors have pro-
found vasodilatory effects, although their usefulness in animal mod-
els of sGC-related diseases remains to be shown. sGC stimulators 
and CO also appear to be useful in preventing neointima formation 
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after percutaneous transluminal interventions. Even more exciting, 
the heme-independent sGC activators allow, for the first time, to se-
lectively target oxidized sGC, thus allowing a site-directed effect in 
diseased vessels. These substances are especially promising for the 
treatment of late-stage atherosclerosis and other vascular diseases 
that result in excessive oxidative stress, as the vessels exhibit a sec-
ondary "NO resistance syndrome" which renders them mostly inac-
cessible to the salutary effects of NO donors and sGC stimulators. 
However,  beneficial  effects  of  these  substances  have  also  been 
shown in animal models of pulmonary hypertension and of heart 
failure, as well as in a preliminary study involving patients suffering 
from  decompensated  heart  failure.  In  contrast,  the  evidence  for 
long-term beneficial effects of sGC inhibition in vasoplegia and hy-
potension is still scarce. Although the improvement of the hemody-
namics and of the oxygen delivery are undisputed, an improvement 
of the mortality still remains to be shown.
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